ENVIRONMENTAL, SOCIAL AND GOVERNANCE (ESG) CONTINUED The Board is highly engaged in the oversight and direction of the business. Five members served during the year to 31 December 2025, as set out in the table below. Details of the relevant skills, experience and expertise of each Board member are set out on page 21 of this report. Appointment Retirement Role Independent Committees Patrick Davies Appointment as director: 2018 Appointment as Chair: 2020 Non-executive chair Yes Member of Audit Committee and Remuneration Committee Dianne Angus 2018 Non-executive director Yes Member of Audit Committee and Remuneration Committee Jenny Harry 2018 Non-executive director Yes Member of Audit Committee and Chair of Remuneration Committee Jon Pilcher 2021 Chief Executive Officer and Managing Director No1 Joe Basile 2023 Non-executive director Yes Chair of Audit Committee and member of Remuneration Committee 1 Jon Pilcher is not considered independent due to his executive role. There is a majority of independent directors in accordance with Recommendation 2.4. The chair is independent and the chair and chief executive officer roles are separate (Recommendation 2.5). The directors believe that the structure and membership profile of the Board has provided and continues to provide the maximum value to the business at this stage of its development. In accordance with Recommendation 2.6, the Company has a program for inducting new directors and provides appropriate professional development opportunities for directors to develop and maintain the skills and knowledge needed to perform their role as directors effectively. PRINCIPLE 3. INSTIL A CULTURE OF ACTING LAWFULLY, ETHICALLY AND RESPONSIBLY In accordance with Recommendation 3.1, the Group has articulated its values, which are disclosed on the Company website. – We are passionate about making a difference to the lives of patients and their families – We aim to earn the respect of everyone we deal with – We are determined and creative to break through barriers – We harness the power of collaboration and different perspectives – We apply a quality mindset to everything we do – We recognise the importance of all stakeholders and endeavour to use financial resources efficiently The Board approved an updated Code of Conduct in 2025 (Recommendation 3.2), which sets out the standards of ethical behaviour, integrity and professionalism expected of all directors, key executives, consultants and employees. Its purpose is to: – support high standards of governance and ethical conduct – promote decision‑making in a manner consistent with the best interests of the Company and its shareholders – promote accountability, transparency and responsible leadership – provide clear expectations for conduct, judgement and behaviour Neuren is committed to the highest standards of conduct and ethical behaviour in all business activities. The Group’s Whistleblower Policy is available on the Company website (Recommendation 3.3). Any material breaches of the Whistleblower Policy are to be reported to the Board. Neuren Pharmaceuticals Limited Annual Report 2025 27
RkJQdWJsaXNoZXIy MjE2NDg3